Sodium glucose cotransporter 2 (SGLT2) inhibitors, originally developed for the treatment of type 2 diabetes mellitus (T2DM), are clinically very effective drugs halting chronic kidney disease (CKD) progression (13). The gene discussed is SLC5A2; the disease is chronic kidney disease.